BSIM Therapeutics Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
BSIM Therapeutics General Information
Description
Developer of biotechnology company designed to address transthyretin-mediated amyloidosis and its related clinical manifestations. The company offers treatments targeting conditions such as hereditary ATTR amyloidosis with polyneuropathy, and cardiomyopathy, enabling patients to manage a broader range of symptoms, including oculopathy, central nervous system complications, and heart-related pathologies.
Contact Information
Website
www.bsimtx.comCorporate Office
- Instituto Pedro Nunes
- Rua Pedro Nunes, Edifício C, Sala 2.15
- Coimbra, 3030-199
- Portugal
Corporate Office
- Instituto Pedro Nunes
- Rua Pedro Nunes, Edifício C, Sala 2.15
- Coimbra, 3030-199
- Portugal
BSIM Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 25-Dec-2024 | Completed | Out of Business | |||
| 7. Grant | 15-Feb-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 01-Aug-2019 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Accelerator/Incubator | 10-Jun-2019 | Completed | Generating Revenue | |||
| 3. Seed Round | 23-Jun-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
BSIM Therapeutics Patents
BSIM Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180208570-A1 | Bis-furan derivatives as transthyretin (ttr) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (fap) | Active | 15-Jun-2015 | ||
| US-10377729-B2 | Bis-furan derivatives as transthyretin (ttr) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (fap) | Active | 15-Jun-2015 | ||
| US-20190092737-A1 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Active | 21-Nov-2014 | ||
| EP-3221299-A1 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Pending | 21-Nov-2014 | ||
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Active | 21-Nov-2014 | A61K31/426 |
BSIM Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BSIM Therapeutics FAQs
-
When was BSIM Therapeutics founded?
BSIM Therapeutics was founded in 2011.
-
Where is BSIM Therapeutics headquartered?
BSIM Therapeutics is headquartered in Coimbra, Portugal.
-
What is the size of BSIM Therapeutics?
BSIM Therapeutics has 3 total employees.
-
What industry is BSIM Therapeutics in?
BSIM Therapeutics’s primary industry is Biotechnology.
-
Is BSIM Therapeutics a private or public company?
BSIM Therapeutics is a Private company.
-
What is BSIM Therapeutics’s current revenue?
The current revenue for BSIM Therapeutics is .
-
How much funding has BSIM Therapeutics raised over time?
BSIM Therapeutics has raised $1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
